Cover Image
市場調查報告書

Cellerant Therapeutics, Inc.- 產品平台檢討

Cellerant Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293979
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Cellerant Therapeutics, Inc.- 產品平台檢討 Cellerant Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 23 Pages
簡介

Cellerant Therapeutics, Inc.是總公司設在美國的製藥企業,進行對腫瘤及血液相關疾病的人類幹細胞產品及抗體治療藥的開發。為了開發急性骨髓性白血病、多發性骨髓瘤、骨髓發育不良症候群等治療藥,實施癌症幹細胞的抗體開發計劃。

本報告提供Cellerant Therapeutics, Inc.的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Cellerant Therapeutics, Inc.的基本資料

  • Cellerant Therapeutics, Inc.概要
  • 主要資訊
  • 企業資料

Cellerant Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Cellerant Therapeutics, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Cellerant Therapeutics, Inc.:開發中產品概況

  • 在臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Cellerant Therapeutics, Inc.:藥物簡介

  • romyelocel-L
  • CLT-009
  • Antibody to Target Cancer Stem Cell for Cancer

Cellerant Therapeutics, Inc.:開發平台分析

  • 各給藥途徑
  • 各分子類型

Cellerant Therapeutics, Inc.:最近的開發平台資訊

Cellerant Therapeutics, Inc.:開發暫停中的計劃

Cellerant Therapeutics, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07037CDB

Summary

Global Markets Direct's, 'Cellerant Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Cellerant Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cellerant Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Cellerant Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Cellerant Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Cellerant Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Cellerant Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Cellerant Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Cellerant Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Cellerant Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellerant Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Cellerant Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Cellerant Therapeutics, Inc. Snapshot
    • Cellerant Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Cellerant Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Cellerant Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Cellerant Therapeutics, Inc. - Pipeline Products Glance
    • Cellerant Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Cellerant Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Cellerant Therapeutics, Inc. - Drug Profiles
    • romyelocel-L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CLT-009
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody to Target Cancer Stem Cell for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Cellerant Therapeutics, Inc. - Pipeline Analysis
    • Cellerant Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Cellerant Therapeutics, Inc. - Pipeline Products by Molecule Type
  • Cellerant Therapeutics, Inc. - Recent Pipeline Updates
  • Cellerant Therapeutics, Inc. - Dormant Projects
  • Cellerant Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Cellerant Therapeutics, Inc., Key Information
  • Cellerant Therapeutics, Inc., Key Facts
  • Cellerant Therapeutics, Inc. - Pipeline by Indication, 2015
  • Cellerant Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Cellerant Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Cellerant Therapeutics, Inc. - Phase II, 2015
  • Cellerant Therapeutics, Inc. - Phase I, 2015
  • Cellerant Therapeutics, Inc. - Preclinical, 2015
  • Cellerant Therapeutics, Inc. - Discovery, 2015
  • Cellerant Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Cellerant Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Cellerant Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Cellerant Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Cellerant Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Cellerant Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Cellerant Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Cellerant Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Cellerant Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top